CN110117278B - 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 - Google Patents

烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 Download PDF

Info

Publication number
CN110117278B
CN110117278B CN201810124854.9A CN201810124854A CN110117278B CN 110117278 B CN110117278 B CN 110117278B CN 201810124854 A CN201810124854 A CN 201810124854A CN 110117278 B CN110117278 B CN 110117278B
Authority
CN
China
Prior art keywords
formula
compound
membered
benzo
dmso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810124854.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110117278A (zh
Inventor
叶德泳
莫明广
杨金童
周璐
楚勇
费金钰
齐翔宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shijiazhuang Yiling Pharmaceutical Co Ltd
Original Assignee
Shijiazhuang Yiling Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Yiling Pharmaceutical Co Ltd filed Critical Shijiazhuang Yiling Pharmaceutical Co Ltd
Priority to CN201810124854.9A priority Critical patent/CN110117278B/zh
Priority to US16/967,118 priority patent/US11396504B2/en
Priority to JP2020542775A priority patent/JP7475049B2/ja
Priority to EP19751009.2A priority patent/EP3750890B1/en
Priority to PCT/CN2019/072468 priority patent/WO2019154047A1/zh
Publication of CN110117278A publication Critical patent/CN110117278A/zh
Application granted granted Critical
Publication of CN110117278B publication Critical patent/CN110117278B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201810124854.9A 2018-02-07 2018-02-07 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 Active CN110117278B (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201810124854.9A CN110117278B (zh) 2018-02-07 2018-02-07 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
US16/967,118 US11396504B2 (en) 2018-02-07 2019-01-21 Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof
JP2020542775A JP7475049B2 (ja) 2018-02-07 2019-01-21 アルコキシベンゾ五員（六員）複素環式アミン化合物およびその医薬用途
EP19751009.2A EP3750890B1 (en) 2018-02-07 2019-01-21 Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof
PCT/CN2019/072468 WO2019154047A1 (zh) 2018-02-07 2019-01-21 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810124854.9A CN110117278B (zh) 2018-02-07 2018-02-07 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途

Publications (2)

Publication Number Publication Date
CN110117278A CN110117278A (zh) 2019-08-13
CN110117278B true CN110117278B (zh) 2022-07-19

Family

ID=67519628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810124854.9A Active CN110117278B (zh) 2018-02-07 2018-02-07 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途

Country Status (5)

Country Link
US (1) US11396504B2 (https=)
EP (1) EP3750890B1 (https=)
JP (1) JP7475049B2 (https=)
CN (1) CN110117278B (https=)
WO (1) WO2019154047A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
CN110117278B (zh) 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
CN111481548A (zh) * 2019-01-29 2020-08-04 复旦大学 4-(2,6-二氯苄氧基)-3-(3-氨基吡啶)苯并[d]异噁唑在制药中的用途
CN113616652A (zh) * 2020-05-06 2021-11-09 石家庄以岭药业股份有限公司 Sms2抑制剂在制备治疗高侵袭性乳腺癌药物中的应用
CN116854670A (zh) * 2022-03-28 2023-10-10 中国科学院上海药物研究所 一类二氢喹喔啉类选择性溴结构域识别蛋白抑制剂及其制备方法和用途
CN119320385A (zh) * 2023-07-17 2025-01-17 复旦大学 烷氧基噻吩甲酰芳胺类化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080395A (zh) * 2004-10-14 2007-11-28 特拉梅克斯实验室 吲唑、苯并异噁唑和苯并异噻唑及其作为雌激素药物的用途
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
CN105348182A (zh) * 2014-08-24 2016-02-24 复旦大学 2-烷氧基苯甲酰芳胺类化合物及其药物用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
HUP9802492A3 (en) * 1995-06-06 1999-10-28 Hoechst Marion Roussel Inc Cin Benzisoxazole and indazole derivatives as antipsychotic agents, process for their preparation and pharmaceutical compositions containing the same
US5668154A (en) * 1995-06-06 1997-09-16 Hoechst Marion Roussel Inc. Pyridiniminyl-1,2-benzisoxazoles and -benzisothiazoles
GB9914486D0 (en) * 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
RU2006134022A (ru) * 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
JP5314244B2 (ja) * 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
EP1856099A2 (en) * 2005-03-03 2007-11-21 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
WO2006094235A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
CN101213187B (zh) * 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
JP2009520825A (ja) * 2005-12-20 2009-05-28 武田薬品工業株式会社 グルコキナーゼ活性剤
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
ATE549325T1 (de) * 2007-01-26 2012-03-15 Basf Se 3-amino-1,2-benzisothiazol-verbindungen zur bekämpfung von tierpest ii
MX2009008531A (es) * 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
WO2008156757A1 (en) * 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
JP2010111624A (ja) * 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
CN101993382B (zh) * 2009-08-21 2014-10-29 复旦大学 芳香胺类衍生物或其类似物及其应用
JP6661192B2 (ja) 2016-01-19 2020-03-11 国立大学法人北海道大学 Ｓｍｓ２阻害活性を有するセラミド誘導体
CN110117278B (zh) 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080395A (zh) * 2004-10-14 2007-11-28 特拉梅克斯实验室 吲唑、苯并异噁唑和苯并异噻唑及其作为雌激素药物的用途
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
CN105348182A (zh) * 2014-08-24 2016-02-24 复旦大学 2-烷氧基苯甲酰芳胺类化合物及其药物用途

Also Published As

Publication number Publication date
EP3750890A1 (en) 2020-12-16
JP7475049B2 (ja) 2024-04-26
JP2021512913A (ja) 2021-05-20
EP3750890A4 (en) 2021-08-11
EP3750890B1 (en) 2026-04-01
US11396504B2 (en) 2022-07-26
WO2019154047A1 (zh) 2019-08-15
CN110117278A (zh) 2019-08-13
US20210032230A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
CN110117278B (zh) 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
CN115335379B (zh) 含螺环的喹唑啉化合物
JP7301222B2 (ja) Ｐｒｍｔ５阻害剤としての置換三環類化合物及びその応用
CN107922425B (zh) 制备parp抑制剂、结晶形式的方法及其用途
EP3740206B1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP7128345B2 (ja) ジアリール大員環化合物、医薬組成物及びその用途
CN117157297A (zh) Prmt5抑制剂
WO2019191620A1 (en) Crystalline forms of modulators of cftr
CN103848785A (zh) 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
JP6644770B2 (ja) ２−アルコキシベンゾイル芳香族アミン化合物及びその薬物の用途
JP7041821B2 (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
CN107793371B (zh) 一类溴结构域识别蛋白抑制剂及其制备方法和用途
CN108329330B (zh) 2-苄氧苯基噁唑并吡啶类化合物及其药物用途
CN106608869B (zh) 一类组蛋白去甲基化酶jmjd3抑制剂及其制备方法和用途
CN116655638B (zh) 氘代prmt5抑制剂
CN119176814A (zh) 一种prmt5抑制剂及其用途
CN105439914B (zh) 4‑氨酰基苯氧乙酰胺类化合物及其药物用途
CN101993382B (zh) 芳香胺类衍生物或其类似物及其应用
CN103833671A (zh) 一类二氢噻唑酮类化合物及其药物组合物和用途
CN116143708A (zh) 一种多取代苯并氮杂芳基衍生物及其用途
CN104177342B (zh) 杂环基取代的吲哚并萘酮衍生物及其医药用途
CN108341774A (zh) 取代的喹啉酮类抑制剂
JP2023502279A (ja) Ｃｐｓ１を阻害するためのピペラジン化合物
WO2023125947A1 (zh) 四氢异喹啉类化合物的可药用盐、晶型及其用途
CN110950890B (zh) 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210324

Address after: 050035 no.238 Tianshan Street, high tech Industrial Development Zone, Shijiazhuang City, Hebei Province

Applicant after: Shijiazhuang Yiling Pharmaceutical Co.,Ltd.

Address before: 200433 No. 220, Handan Road, Shanghai, Yangpu District

Applicant before: FUDAN University

GR01 Patent grant
GR01 Patent grant